SCHEMBL6475576

SCHEMBL6475576

CCN(CC)c1ccc(CCCc2ccc(Nc3cc([N+](=O)[O-])c(C(=O)O)cc3OC)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
LMNA P02545 2/20 0.46
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
MEN1 O00255 3/20 0.41
ABCB1 P08183 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
CTSV O60911 3/20 0.41
CTSL P07711 3/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6528594 0.81 MEN1 (0.48) MAPTLMNAKMT2AALDH1A1NPSR1
SCHEMBL6481662 0.80 CTSV (0.58) MAPTLMNAKMT2AALDH1A1CYP1A2
SCHEMBL6475709 0.79 MAPT (0.43) MAPTLMNAKMT2AALDH1A1NPSR1
SCHEMBL6484033 0.78 KMT2A (0.43) MAPTLMNAKMT2AALDH1A1MEN1
SCHEMBL6484538 0.77 MEN1 (0.58) MAPTLMNAKMT2AALDH1A1MEN1
SCHEMBL6474913 0.74 MEN1 (0.55) MAPTLMNAKMT2AALDH1A1RECQL
SCHEMBL6474642 0.73 KMT2A (0.52) MAPTLMNAKMT2AALDH1A1RECQL
SCHEMBL6476158 0.73 KMT2A (0.52) MAPTLMNAKMT2ARECQLMEN1
SCHEMBL6474231 0.71 MAPT (0.56) MAPTLMNAKMT2AALDH1A1RECQL
SCHEMBL6482333 0.70 KMT2A (0.51) MAPTLMNAKMT2AALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MAPT 6/4885LMNA 876/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.